• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 159

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a Psychedelic Informed World

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab

Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

FILAMENT HEALTH ISSUED THIRD PATENT BY UNITED STATES PATENT AND TRADEMARK...

PT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic...

Psychedelic Research Bulletin: June 2022

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules...

FILAMENT HEALTH ANNOUNCES FIRST DOSING IN GROUNDBREAKING FDA-APPROVED PSILOCIN CLINICAL TRIAL

PT335 – Christopher Dawson & Andrew Galloway – Modernizing Traditional Plant...

Tripping the Reward Circuit: Psychedelics for Substance Use Disorders

Psychedelic Drugs Market Reaches US$6330.0 Mn by 2026 from US$3210.0 Mn...

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

1...158159160...301Page 159 of 301

EDITOR PICKS

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a...

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©